Ipsen and Inspiration Biopharmaceuticals Enter into Partnership to Create a World Leading Hemophilia Franchise
- Portfolio covers all major hemophilia markets and worldwide sales could exceed $1.0 billion by 2020
- Following the exclusive in-licensing of Ipsen’s OBI-1 alongside its own IB1001, Inspiration’s portfolio now includes two recombinant protein products ready to enter Phase III in 2010 and two earlier development compounds for the treatment of bleeding disorders
- Ipsen to acquire initial 20% stake in Inspiration for $85 million with the potential to increase ownership up to 47% through up to $174 million in additional milestone-based funding
About this entry
You’re currently reading “Ipsen and Inspiration Biopharmaceuticals Enter into Partnership to Create a World Leading Hemophilia Franchise,” an entry on The Coalition for Hemophilia B
- Published:
- 01.24.10 / 10am
- Category:
- Press Release
Comments are closed
Comments are currently closed on this entry.